Meropenem Acs Dobfar (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem used for severe bacterial infections across several organ systems.

• Complicated intra‑abdominal infections: provides rapid bacterial eradication in severe abdominal sepsis.
• Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis and cystitis.
• Nosocomial pneumonia: treats hospital‑acquired and ventilator‑associated lung infections.
• Meningitis: penetrates the cerebrospinal fluid to clear central nervous system infections.
• Sepsis: offers bactericidal activity in systemic bloodstream infections.
• Skin and soft tissue infections: resolves deep tissue and necrotizing infections caused by Gram‑negative organisms.

• Meropenem binds to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability, cell lysis, and bacterial death. Its broad affinity for multiple PBPs underlies its activity against many Gram‑negative, Gram‑positive and anaerobic organisms, including many resistant strains.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional emesis during or after infusion.
• Diarrhea: loose stools, sometimes watery.
• Headache: transient cranial discomfort.
• Rash: mild erythematous skin eruption.
• Phlebitis at infusion site: local irritation or inflammation.

Serious or Rare Side Effects

• Seizures: especially in patients with renal dysfunction or high doses.
• Clostridioides difficile colitis: severe diarrhea due to gut flora disruption.
• Anaphylaxis: acute hypersensitivity reaction with respiratory or cardiovascular compromise.
• Renal toxicity: worsening kidney function in susceptible individuals.
• Hepatic enzyme elevation: transient increase in liver transaminases.
• Neutropenia: marked reduction in white blood cell count.

Careful assessment and monitoring are required before and during therapy.

• Renal function: adjust dose in patients with impaired clearance.
• Allergy: avoid in individuals with known carbapenem hypersensitivity.
• Pregnancy: use only when the potential benefit justifies the risk to the fetus.
• Concomitant valproic acid: monitor for reduced antiepileptic levels.
• Drug interactions: review all concurrent medications for possible effects.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with several agents, requiring clinical vigilance.

Major Interactions (Avoid)

• Valproic acid: carbapenems can markedly reduce serum valproate concentrations, risking seizure breakthrough.
• Cytotoxic chemotherapy: increased risk of myelosuppression when combined.

Moderate Interactions (Monitor Closely)

• Probenecid: may decrease renal excretion of meropenem, raising plasma levels.
• Loop diuretics: potential for enhanced nephrotoxicity, especially in renal impairment.
• Warfarin: occasional alteration of INR, requiring coagulation monitoring.